Lorena Tonarelli, MSc



Therapy Areas

Oncology (e.g., multiple myeloma, leukaemia, lymphoma, and brain, breast, ovarian, lung, kidney, pancreatic, prostate and skin cancers) • Haematology (e.g., haemophilia, von Willebrand disease) • Dermatology (e.g., psoriasis, atopic dermatitis) • Rare diseases (e.g., haemophilia, spinal muscular atrophy, cystic fibrosis) • Neurology (e.g., Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, epilepsy) • Cardiovascular (e.g., stroke, myocardial infarction, heart failure, arrhythmias) • Diabetes and complications (e.g., nephropathy, retinopathy) • Immunodeficiency diseases • Respiratory (e.g., asthma, COPD, influenza) •

Drug Classes

Checkpoint inhibitors (anti PD-1/PD-L1; CTLA-4 mAbs) • LADD-based immunotherapies • PARP inhibitors • Tyrosine kinase inhibitors (VEGFR TKIs, HER2 TKIs) • Adenosine A2A receptor antagonist • CDK4/6 inhibitors • EGFR/cMet bispecific antibodies • Clotting factor concentrates (e.g., PCCs, FCH) • Immunomodulatory agents • PCSK9 inhibitors • SGLT2 inhibitors • Factor Xa inhibitors • Angiotensin receptor-neprilysin inhibitors • Aldosterone synthase inhibitors • Guanylyl cyclase activators • Recombinant human GLP-2 analogues • Anti-TNF monoclonal antibodies • IL-23 inhibitors • IL-4/IL-13 signalling inhibitor • LAMAs; LABAs • CFTR potentiators • Immunoglobulins •

Medical Devices

Sutureless valves for aortic valve replacement •Radiolabelled PET tracers for prostate cancer (e.g., 68Ga PSMA PET, 177Lu PSMA PET) • PET beta-amyloid imaging for in vivo diagnosis of Alzheimer’s disease • Extracorporeal life support devices (ECCO2R) • High-performance aerosol drug delivery systems for COPD and asthma • MRI for the diagnosis and management of brain tumors, stroke, and COPD • Technological innovations for cancer management (e.g., implantable sensors, wearable devices, neurotechnology) •

Print Print | Sitemap
© 2022 Lorena Tonarelli, M.Sc. B.Sc. (Hons)